The EMA has started its review of Daiichi Sankyo and AstraZeneca's Enhertu as a first-line therapy for HER2-positive breast cancer, setting up a possible approval later this year. The two companies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results